{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:59:03Z","timestamp":1791939543400,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004460","name":"Rotary Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01818","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T09:14:02Z","timestamp":1564564442000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":271,"title":["The TNF Paradox in Cancer Progression and Immunotherapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Anne","family":"Montfort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Colacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Levade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Andrieu-Abadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"S\u00e9gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci USA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/312724a0","article-title":"Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin","volume":"312","author":"Pennica","year":"1984","journal-title":"Nature."},{"key":"B3","first-page":"447","article-title":"Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro","volume":"138","author":"Robaye","year":"1991","journal-title":"Am J Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/0092-8674(93)90464-2","article-title":"A novel domain within the 55 kd TNF receptor signals cell death","volume":"74","author":"Tartaglia","year":"1993","journal-title":"Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/00000658-199612000-00011","article-title":"Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. the cumulative multicenter European experience","volume":"224","author":"Eggermont","year":"1996","journal-title":"Ann Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1200\/JCO.1996.14.2.479","article-title":"Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study","volume":"14","author":"Fraker","year":"1996","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/81183","article-title":"Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)","volume":"18","author":"Curnis","year":"2000","journal-title":"Nat Biotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.4049\/jimmunol.1101877","article-title":"Targeting TNF-\u03b1 to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy","volume":"188","author":"Calcinotto","year":"2012","journal-title":"J Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/1078-0432.CCR-17-2210","article-title":"Targeting tumor vasculature with TNF leads effector T cells to the tumor and enhances therapeutic efficacy of immune checkpoint blockers in combination with adoptive cell therapy","volume":"24","author":"Elia","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1158\/1078-0432.CCR-18-1728","article-title":"Antibody-based delivery of TNF to the tumor neovasculature potentiates the therapeutic activity of a peptide anticancer vaccine","volume":"25","author":"Probst","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"Oncoimmunology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"eaar3451","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney","year":"2018","journal-title":"Sci Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmet.2018.05.012","article-title":"Alteration of tumor metabolism by CD4+ T cells leads to TNF-\u03b1-dependent intensification of oxidative stress and tumor cell death","volume":"28","author":"Habtetsion","year":"2018","journal-title":"Cell Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/10552","article-title":"Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis","volume":"5","author":"Moore","year":"1999","journal-title":"Nat Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/sj.onc.1207317","article-title":"Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development","volume":"23","author":"Arnott","year":"2004","journal-title":"Oncogene."},{"key":"B16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/0008-5472.CAN-08-1565","article-title":"Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site","volume":"69","author":"Li","year":"2009","journal-title":"Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1172\/JCI39065","article-title":"The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans","volume":"119","author":"Charles","year":"2009","journal-title":"J Clin Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/0008-5472.CAN-14-2524","article-title":"Blocking tumor necrosis factor \u03b1 enhances CD8 T-cell-dependent immunity in experimental melanoma","volume":"75","author":"Bertrand","year":"2015","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1172\/JCI64115","article-title":"TNF signaling drives myeloid-derived suppressor cell accumulation","volume":"122","author":"Zhao","year":"2012","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"aaf8608","DOI":"10.1126\/scisignal.aaf8608","article-title":"Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated tregs","volume":"10","author":"Torrey","year":"2017","journal-title":"Sci Signal."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1158\/0008-5472.CAN-14-2956","article-title":"Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T- cells, which dampen CD8+ T-cell antitumor reactivity","volume":"75","author":"Donia","year":"2015","journal-title":"Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10662","DOI":"10.1073\/pnas.1100994108","article-title":"B regulatory cells and the tumor-promoting actions of TNF-\u03b1 during squamous carcinogenesis","volume":"108","author":"Schioppa","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature."},{"key":"B24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","article-title":"Immunotherapy resistance by inflammation-induced dedifferentiation","volume":"8","author":"Mehta","year":"2018","journal-title":"Cancer Discov."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1158\/1541-7786.MCR-12-0160","article-title":"TNF-\u03b1 induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3\u03b2-dependent mechanism","volume":"10","author":"Ho","year":"2012","journal-title":"Mol Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1158\/0008-5472.CAN-11-3123","article-title":"Epithelial-mesenchymal transition induced by TNF-\u03b1 requires NF-\u03baB-mediated transcriptional upregulation of Twist1","volume":"72","author":"Li","year":"2012","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-019-00508-8","article-title":"TGF-\u03b21 and TNF-\u03b1 synergistically induce epithelial to mesenchymal transition of breast cancer cells by enhancing TAK1 activation","author":"Liao","year":"2019","journal-title":"J Cell Commun Signal."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1158\/0008-5472.CAN-17-0395","article-title":"MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy","volume":"77","author":"Reinhardt","year":"2017","journal-title":"Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ijc.32080","article-title":"Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs","volume":"145","author":"Draghi","year":"2018","journal-title":"Int J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/CJI.0000000000000268","article-title":"Incidence and clinical impact of anti-TNFalpha treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the mecolit survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J Immunother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","article-title":"A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer","volume":"19","author":"Brown","year":"2008","journal-title":"Ann Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1200\/JCO.2005.04.127","article-title":"Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer","volume":"23","author":"Madhusudan","year":"2005","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","article-title":"Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose","volume":"25","author":"Harrison","year":"2007","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature."}],"updated-by":[{"DOI":"10.3389\/fimmu.2019.02515","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:50:51Z","timestamp":1571705451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2019.01818"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01818","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"article-number":"1818"}}